The suppression of NLRP3 inflammasome activation has demonstrated potential in reducing NSCLC cell proliferation and metastasis [15,16], positioning it as a promising therapeutic target in NSCLC treatment. This evidence concerns the gene NLRP3 and non-small cell lung carcinoma.